All stock lists
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
70.61+2.42 (+3.54%)
Market cap
$3.30B
Health Score
Analyst consensus
Listed since
Oct 16, 2020
Website
Insider Score
––Not scored
TARS Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
TARS analyst forecast
TARS analyst consensus
Moderate Buy3 ratings
Buy 3 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
TARS 12-month price target
$116.00+66.4% upsideaverage of 1 firm
$116.00High
$116.00Low
Best analysts covering TARS
- Guggenheim100%success rate · 8 calls
- Jefferies100%success rate · 2 calls
- Oppenheimer86%success rate · 7 calls
- HC Wainwright & Co.80%success rate · 10 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
TARS analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| Goldman Sachs | — | $116.00 | +56.1% | — | 2026-09-24 | |
| — | Jefferies | Buy | — | — | Reiterated | 2026-09-08 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-08-12 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-07-31 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-07-21 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-04 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2026-02-25 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-02-25 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-11-05 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-10-20 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2025-05-05 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-05-02 |
| — | Jefferies | Buy | — | — | Reiterated | 2025-03-06 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-02-26 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-02-26 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-02-26 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-02-24 |
| — | Guggenheim | Buy | — | — | Reiterated | 2025-02-10 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-01-27 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-01-22 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2024-11-15 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-11-14 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-08-09 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-13 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-05-10 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-05-09 |
| — | Jefferies | Buy | — | — | Reiterated | 2024-03-06 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2024-02-29 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2024-02-28 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-02-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-02-28 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-11-10 |
| — | Guggenheim | Buy | — | — | Reiterated | 2023-09-11 |
| — | Guggenheim | Buy | — | — | Reiterated | 2023-08-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-08-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-07-26 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-06-26 |
| — | Guggenheim | Buy | — | — | Reiterated | 2023-06-16 |
| — | Guggenheim | Buy | — | — | Reiterated | 2023-05-18 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2023-05-08 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2023-03-15 |
| — | Barclays | Overweight | — | — | Reiterated | 2022-08-01 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2021-12-21 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2021-11-23 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2021-10-08 |
| — | Raymond James | Strong Buy | — | — | Reiterated | 2021-06-29 |
| — | Raymond James | Buy | — | — | Downgraded | 2020-11-10 |
| — | B of A Securities | Buy | — | — | Reiterated | 2020-11-10 |
| — | Jefferies | Buy | — | — | Reiterated | 2020-11-10 |
| — | Ladenburg Thalmann | Buy | — | — | Reiterated | 2020-11-10 |
TARS earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-23 | -0.10 | -0.20 | $144.6M | $151.7M |
| 2026-05-06 | -0.40 | -0.16 | $149.6M | $162.1M |
| 2026-08-06 | -0.19 | -0.43 | $169.7M | $173.9M |
| 2026-11-03 | -1.49 | 0.00 | $186.6M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.